Bosentan (Tracleer®)

Assessment Status Rapid Review complete
Drug Bosentan
Brand Tracleer®
Indication Treatment pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO Functional Class (FC) III and WHO FC II.  It is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.
Assessment Process
Rapid review commissioned 27/06/2014
Rapid review completed 04/07/2014
Rapid review outcome Full Pharmacoeconomic Evaluation Not Recommended